Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Geologica Closes Financing And Property Acquisition (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Vaxart Inc VXRT

Healthcare Biotechnology
Vaxart, Inc. is a clinical-stage biotechnology company that is primarily focused on the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology (VAAST) proprietary oral vaccine platform. Its vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Its... see more

Recent & Breaking News (NDAQ:VXRT)

Oral RSV Vaccine - Preclinical Data Published in Vaccine

Business Wire June 27, 2018

Vaxart Reports Topline Results from Phase 2 Trial of Teslexivir™ for the Treatment of Condyloma

Business Wire June 4, 2018

Vaxart to Present at the Jefferies 2018 Global Healthcare Conference

Business Wire June 1, 2018

Vaxart to Present at ASM Microbe 2018

Business Wire May 31, 2018

Vaxart Announces First Quarter 2018 Financial Results and Corporate Update

Business Wire May 15, 2018

Vaxart Appoints Dr. David Taylor as Chief Medical Officer

Business Wire May 1, 2018

Vaxart Announces $5 Million Inavir® Revenue Milestone

Business Wire April 20, 2018

Vaxart Appoints Brant Biehn as Senior Vice President, Commercial Operations

Business Wire April 19, 2018

Vaxart to Present at Two Upcoming Medical Meetings

Business Wire April 16, 2018

Vaxart Announces Oral Presentation of Clinical Data from Oral Influenza Vaccine Program at the World Vaccine Congress

Business Wire April 2, 2018

Vaxart to Present at the 17th Annual Needham Healthcare Conference

Business Wire March 21, 2018

Vaxart Expands Intellectual Property Portfolio With U.S. Patent Allowance

Business Wire March 7, 2018

Vaxart to Present Clinical Data From Oral Norovirus Vaccine Program at International Congress on Infectious Diseases

Business Wire March 2, 2018

Vaxart, Inc. Closes Merger with Aviragen Therapeutics, Inc.

Business Wire February 13, 2018